SAB Biotherapeutics

United States
Sioux Falls, South Dakota, United States, SD 57104

Company profile

SAB Biotherapeutics company profile

A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

Business identity

Contact email
[email protected]
Phone number
(605)679-6980
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2014-06-01, Month

Headquarters

Postal code
SD 57104
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
8
Total equity funding
$351.9M
Last funding
Post IPO Equity / $175M / 2025-07-21
Last equity funding
Post IPO Equity / $175M
Investors
20
Lead investors
5
Founders
2
Articles
103
Exited on
2021-10-25

Founders and investors

Founders

Eddie SullivanEdward Hamilton

Lead investors

National Institutes of HealthRA Capital ManagementSioux Falls Development FoundationSouth Dakota Equity PartnersU.S. Department of Defense

Investors

Commodore CapitalRA Capital ManagementRTW InvestmentsSanofiVivo Capital